BioSpace News Archive

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of August 31, 2023, grants of non-qualified stock options to purchase an aggregate of 59,260 shares of its common stock and restricted stock units covering an aggregate of 29,630 shares of its common stock under the Inducement Plan to four new employees.

Zomedica Corp. announced it has completed the acquisition of Structured Monitoring Products, Inc., the makers of the VetGuardian™ touchless vital signs monitoring technology.

Medexus Pharmaceuticals Inc., is pleased to announce that it has entered into an agreement with Research Capital Corporation, as sole bookrunner and sole underwriter, pursuant to which the Underwriter has agreed to purchase, on a bought-deal basis, 3,389,900 units of the Company at a price of C$2.95 per Unit for gross proceeds to the Company of C$10,000,205.

PHAXIAM Therapeutics, publishes its cash position as of June 30, 2023, and its financial calendar for the second half of 2023.

Werewolf Therapeutics, Inc. announced that management will participate in the following upcoming investor conferences in the month of September:

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) today announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in an oral poster presentation at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference.

Alkermes plc announced that management will participate in fireside chat presentations at two upcoming investor conferences.

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2023 and provided business updates.